Gastroenterology

Back to articles

Alosetron Approved for Women with Irritable Bowel Syndrome

KEY POINT

The first selective serotonin 5-HT3 antagonist indicated for irritable bowel syndrome (IBS), alosetron (Lotronex—Glaxo Wellcome), will be available to pharmacies in mid-March. It is indicated for use in women who have IBS-associated abdominal pain and discomfort and for whom diarrhea is a primary symptom.